Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.
Sara A. Hurvitz, MD, director, Breast Cancer Clinical Research Program, co-director, Santa Monica University of California, Los Angeles (UCLA) Outpatient Hematology/Oncology Practice, associate professor of medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA, discusses the rationale for the phase 2 coopERA Breast Cancer trial (NCT04436744) in estrogen receptor (ER)–positive, HER2-negative breast cancer.
Currently, fulvestrant (Faslodex) is the only selective ER downregulator (SERD) available for use in metastatic ER-positive breast cancer and it appears to be more efficacious vs single-agent aromatase inhibitors (AIs), Hurvitz says. However, fulvestrant is administered through an intramuscular injection, which is inconvenient for patients, and its oral bioavailability is low.
Giredestrant is an oral SERD that is being evaluated as a potential treatment for patients with ER-positive breast cancer, Hurvitz says. The agent has demonstrated early signs of efficacy, potency, and tolerability among patients with metastatic ER-positive breast cancer. As such, the coopERA Breast Cancer study was developed to evaluate the biological activity of giredestrant vs the AI anastrozole, Hurvitz concludes.